A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monotherapy
Erstveröffentlichung
2012
Wissenschaftlicher Artikel
Published in
Annals of Oncology ; 23 (2012), 9. - S. 2265-2271. - ISSN 0923-7534. - eISSN 1569-8041
Link to publication
https://dx.doi.org/10.1093/annonc/mds003Institutions
UKU. Klinik für Frauenheilkunde und GeburtshilfeSubject headings
[Free subject headings]: angiogenesis inhibitor | ovarian cancer | platinum resistant | sunitinib | RECURRENT EPITHELIAL OVARIAN | ENDOTHELIAL GROWTH-FACTOR | ANTITUMOR-ACTIVITY | INTERGROUP TRIAL | CARCINOMA | PACLITAXEL | CARBOPLATIN | GUIDELINES | CISPLATIN[DDC subject group]: DDC 610 / Medicine & health